Treatment window for Fragile X likely doesn't close after childhood

March 20, 2017 by Frank Otto
Sections of the hippocampus of a 44-year-old person that show Fragile X granules (the bright points at the top of the image) and neuronal cell bodies (the green structures) with FMRP localizing to both. Credit: Michael Akins

Brain samples from humans show that the treatment window for Fragile X syndrome likely remains open well into maturity after childhood, when previous tests with mice indicated it might close, according to a new Drexel University-led study.

This new information could become valuable as therapeutic treatments for Fragile X syndrome—the most common autism-related disorder which results in intellectual disabilities and impacts one in every 4,000 males and one in every 8,000 females—are still being developed in clinical trials.

Michael Akins, PhD, an assistant professor in Drexel's College of Arts and Sciences, led a team that found structures called Fragile X granules in the part of the brain that controls memory, the hippocampus, well into maturity in both rat and human specimens. The granules, which Akins helped discover in 2009, are thought to contribute to Fragile X syndrome when they become decoupled from a gene called FMRP (Fragile X mental retardation protein) that is mutated in Fragile X patients.

While Fragile X granules were found in the brains of adult rats and humans, they seemed to disappear in mice when they reached maturity.

"It's intriguing that this disease-related gene has different expression patterns in humans than in the major preclinical model, mice, that are used to study that gene," Akins said.

As a result, most studies would have missed the evidence of these granules in adulthood because they used mice.

Finding that Fragile X granules linger in the hippocampus of adult humans could expand the age range for treatment. In Akins's study, one human brain sample, from a person 57 years old, showed evidence of the granules. This suggests that treatment could be applied into adulthood, not just during childhood.

Moreover, they also found that treatment might need to target the nerve cells that house FMRP and Fragile X granules more broadly.

These cells, called neurons, have two parts—dendrites and axons—that relay information in the brain. Most research focuses on the FMRP in the dendrites—the information receivers. But past research by Akins and company showed that FMRP was also found in Fragile X granules in the axons—the information senders. However, what the FMRP was doing in these axon granules was not known and work from several other labs suggested that the FMRP in axons might be quite different from the FMRP in dendrites.

In the new study, Akins and colleagues gained insight this. They found that FMRP in axons shares some unexpected similarities to the FMRP in dendrites. This means that therapies that target those similarities might fill in for the lost FMRP in both parts of the cell.

This could be an important development because half of those with Fragile X syndrome could also be diagnosed with autism spectrum disorder. Developments in therapy for Fragile X might play a role in treating symptoms in other types of autism, too.

"It's possible that the symptoms caused by dysregulated Fragile X aren't being addressed by current experimental therapeutic interventions that focus on rescuing FMRP function in the dendrites," Akins said. "What we found is important because having one medication that targets both dendrites and axons should better treat the symptoms of Fragile X and, with luck, other autism-related disorders."

With evidence pointing toward a longer timeframe for possibly effective treatment and a whole new pathway for delivering it, Akins hopes to continue solving the machinations behind Fragile X syndrome.

"We're still trying to understand what the FMRP is doing in the axons—and how its absence from axons contributes to Fragile X—but this is a major step forward," Akins said. "We have some new leads."

Explore further: Study implicates glial cells in fragile X syndrome

More information: Michael R. Akins et al, Axonal ribosomes and mRNAs associate with fragile X granules in adult rodent and human brains, Human Molecular Genetics (2017). DOI: 10.1093/hmg/ddw381

Related Stories

Study implicates glial cells in fragile X syndrome

October 4, 2016
Research on fragile X syndrome, the most common inherited cause of mental retardation, has focused mostly on how the genetic defect alters the functioning of neurons in the brain. A new study focusing on a different type ...

Study identifies new trigger mechanism for fragile X syndrome in mice

July 5, 2016
A study published today in the Journal of Neuroscience led by Yongjie Yang of Tufts University School of Medicine identifies an astroglial trigger mechanism as contributing to symptoms of fragile X syndrome in mice.

Research points to potential treatment strategy for Fragile X syndrome

April 17, 2014
With no cure available, Fragile X syndrome is the most common form of inherited intellectual disability. Individuals with the syndrome cannot produce enough of a protein—called the fragile X mental retardation protein (FMRP)—whose ...

Fragile X proteins involved in proper neuron development

June 10, 2015
Fragile X syndrome is the most common inherited intellectual disability and the greatest single genetic contributor to autism. Unlocking the mechanisms behind fragile X could make important revelations about the brain.

New clue found for Fragile X syndrome-epilepsy link

April 12, 2011
Individuals with fragile X syndrome, the most common inherited form of intellectual disability, often develop epilepsy, but so far the underlying causes are unknown. Researchers have now discovered a potential mechanism that ...

Recommended for you

Presurgical imaging may predict whether epilepsy surgery will work

December 11, 2017
Surgery to remove a part of the brain to give relief to patients with epilepsy doesn't always result in complete seizure relief, but statisticians at Rice University have developed a method for integrating neuroimaging scans ...

Selecting sounds: How the brain knows what to listen to

December 11, 2017
How is it that we are able—without any noticeable effort—to listen to a friend talk in a crowded café or follow the melody of a violin within an orchestra?

Updated brain cell map connects various brain diseases to specific cell types

December 11, 2017
Researchers have developed new single-cell sequencing methods that could be used to map the cell origins of various brain disorders, including Alzheimer's, Parkinson's, schizophrenia and bipolar disorder.

Scientists discover new way to help nerve regeneration in spinal cord injury

December 11, 2017
There is currently no cure for spinal cord injury or treatment to help nerve regeneration so therapies offering intervention are limited. People with severe spinal cord injuries can remain paralysed for life and this is often ...

How a seahorse-shaped brain structure may help us recognize others

December 8, 2017
How do we recognize others? How do we know friend from foe, threat from reward? How does the brain compute the multitude of cues telling us that Susan is not Erica even though they look alike? The complexity of social interactions—human ...

Brain networks that help babies learn to walk ID'd

December 8, 2017
Scientists have identified brain networks involved in a baby's learning to walk—a discovery that eventually may help predict whether infants are at risk for autism.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.